Premium
IAEA activities in support of production and utilization of radioisotope labelled compounds
Author(s) -
Ramamoorthy Natesan,
Pillai Maroor Raghavan Ambikalmajan,
Jin JoonHa,
HajiSaeid Seyed Mohammad
Publication year - 2007
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.1203
Subject(s) - chemistry , radiochemistry , radionuclide therapy , lutetium , nuclear medicine , yttrium , medicine , organic chemistry , oxide
The development of a large variety of radioisotope labelled compounds as well as the ability to design and prepare specific products forms the basis for several important applications in medicine, industry and research. As a part of the IAEA's role in fostering the peaceful uses of nuclear science and technology, the IAEA's Division of Physical and Chemical Sciences has focused attention on the important classes of compounds such as, fluorine‐18 products; technetium‐99m labelled complexes; products for radionuclide therapy of yttrium‐90, samarium‐153, lutetium‐177 and rhenium‐186/188; industrial radiotracers based on bromine‐82 labelled compounds, tritiated water and carbon‐14 labelled thiocyanate. A number of coordinated research projects (CRP) and technical cooperation projects have been implemented for this purpose. Thematic technical and consultancy meetings have been held to review the status and prepare technical documents on specific topics of interest for developing Member States (MS). These measures have contributed to several developing MS acquiring/enhancing expertise in building local facilities and capability in the production and utilization of radioisotope labelled compounds. Copyright © 2007 John Wiley & Sons, Ltd.